David Mott is a seasoned private investor and healthcare executive with extensive experience in the biopharmaceutical sector. Current roles include Chairman of Ardelyx, Inc., Mersana Therapeutics, Adaptimmune, and previously Imara, Inc., and Epizyme, demonstrating strong leadership in advancing innovative therapies. As a Board Member for organizations such as Polyneuron Pharmaceuticals AG and Tiburio Therapeutics, Mott contributes valuable insights to the biotechnology field. Between 2008 and 2020, Mott served as General Partner at New Enterprise Associates (NEA), where leadership in healthcare investing involved deploying approximately $1 billion in venture capital. Mott holds a Bachelor’s Degree in Economics and Government from Dartmouth College and graduated from Saint James School.
This person is not in the org chart
This person is not in any teams
This person is not in any offices